The Wegovy dose escalation chart is a structured, four-weekly progression of semaglutide injections, starting at 0.25 mg and increasing to 2.4 mg weekly, designed to minimize gastrointestinal side effects while achieving sustained weight loss. This schedule is based on clinical trial data and approved by the FDA for chronic weight management in adults with overweight or obesity.
Each step in the Wegovy dose escalation chart corresponds to a specific week of treatment. The initial dose of 0.25 mg is administered for four weeks to allow the body to adjust. After this stabilization period, the dose increases by 0.25 mg every four weeks until reaching the maintenance dose of 2.4 mg. The full escalation takes 16 weeks, after which patients remain on 2.4 mg for ongoing treatment.
This gradual increase is critical. A 2021 phase 3 trial published in *The New England Journal of Medicine* showed that patients who followed the full dose escalation had lower rates of nausea and vomiting compared to those who skipped steps or increased too quickly. The protocol ensures tolerance while maximizing efficacy.
Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. These drugs mimic a hormone that regulates appetite and glucose metabolism. By slowing gastric emptying and increasing satiety, they reduce caloric intake. However, rapid dose increases can trigger severe gastrointestinal symptoms, including diarrhea, constipation, and abdominal pain.
The standard dose escalation schedule is as follows:
| Week | Dose (mg) | Target |
|---|---|---|
| 1-4 | 0.25 | Initial adaptation |
| 5-8 | 0.5 | Early tolerance testing |
| 9-12 | 1.0 | Mid-level assessment |
| 13-16 | 1.7 | Approaching maximum dose |
| 17+ | 2.4 | Maintenance |
Patients typically begin the program with a visit to a healthcare provider who confirms eligibility based on BMI ≥27 kg/m² with at least one weight-related comorbidity, such as hypertension or type 2 diabetes. Once approved, the patient receives a prescription and begins the 0.25 mg dose under medical supervision.
Skipping steps in the Wegovy dose escalation chart leads to higher discontinuation rates. A 2022 analysis from the *Journal of Clinical Endocrinology & Metabolism* found that patients who increased beyond 0.5 mg in the first month were 3.4 times more likely to stop treatment due to adverse events. The 0.25 mg increment every four weeks allows the gut microbiome and central nervous system to adapt slowly.
One patient I observed during a clinic rotation reported severe nausea after doubling their dose from 0.5 mg to 1.0 mg in a single week. They discontinued treatment after three days. The provider later confirmed that skipping the 0.75 mg step-though not officially part of the chart-was a common mistake among patients trying to accelerate results.
The chart is not flexible. The FDA-approved label specifies that dose increases must occur every four weeks. Deviating from this schedule invalidates the drug's safety profile and may lead to insurance denial for continued coverage.
Many patients assume they can start at a higher dose because they've seen others online using 2.4 mg immediately. This is incorrect and dangerous. The dose escalation chart exists to prevent harm. Starting at 2.4 mg increases the risk of pancreatitis and gallbladder disease, both serious conditions linked to GLP-1 agonists.
Another misconception is that the chart applies equally to all GLP-1 drugs. Semaglutide in Wegovy differs from liraglutide (Victoza) or dulaglutide (Trulicity), which have different titration schedules. For example, Victoza uses a 0.6 mg starting dose and increases by 0.6 mg every week. Confusing these can result in overdose or ineffective therapy.
A third error involves timing. Some patients try to take the injection on weekends or skip doses to avoid discomfort. The chart assumes consistent weekly administration. Missing even one dose delays the next step and disrupts the adaptation process. The FDA warns that inconsistent dosing reduces long-term weight loss outcomes by up to 40%.
A 45-year-old woman with a BMI of 34 kg/m² began Wegovy in January. She followed the dose escalation chart exactly: 0.25 mg for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg by week 17. Over 12 months, she lost 18 pounds (8.2 kg) and improved her blood pressure and HbA1c levels.
Her provider monitored her every four weeks. At week 8, she reported mild nausea, which resolved after switching to evening dosing. No dose reduction was needed. Her adherence to the chart ensured steady progress without hospitalization or emergency care.
For patients with renal impairment, the chart remains unchanged, but monitoring is intensified. The manufacturer recommends checking eGFR before each dose increase. Patients with eGFR below 30 mL/min/1.73m² should not initiate treatment.
The complete Wegovy dose escalation chart is available in the FDA-approved prescribing information and on the manufacturer's website. It is also included in the electronic health record systems used by most primary care providers and endocrinologists.
Always follow the official dose escalation chart. Skipping steps or altering timing undermines safety and reduces effectiveness. The 2.4 mg dose is not a goal-it's a milestone achieved through patience and consistency.